Salarius Pharmaceuticals (NASDAQ:SLRX) has appointed Scott Jordan as chief business officer (CBO) and Mark Rosenblum as EVP finance and interim CFO. Mr. Jordan has been Salarius’ CFO since 2016. As CBO, he will lead...
Akari Therapeutics (NASDAQ:AKTX) received FDA orphan drug designation for nomacopan for the treatment of bullous pemphigoid (BP). BP is a severe orphan inflammatory skin disease characterized by chronic blistering of...
Neil McFarlane Adamas Pharmaceuticals (NASDAQ:ADMS) has appointed Neil McFarlane as CEO and a member of its board, effective Sept. 16. Gregory Went, Adamas’ founder, chairman and CEO, will transition to a strategic...
Roth Capital Partners launched coverage of Cellectar Biosciences (NASDAQ:CLRB) with a “buy” rating and $11 price target. The stock closed at $2.29 on Sept. 12. Cellectar is developing CLR 131, a targeted...
Helius Medical Technologies (NASDAQ:HSDT; TSX:HSM) is opening a new PoNS clinic in Quebec City, Canada to be operated by Clinique Cortex. The PoNS device is authorized in Canada for the acute treatment of chronic...
BTIG raised its price target for Eidos Therapeutics (NASDAQ:EIDX) to $56 from $38 after a committee of the board unanimously rejected a share exchange offer from its parent company, BridgeBio Pharma, (NASDAQ:BBIO) to...
Analysts for Alliance Global Partners and SVB Leerink raised their price targets for T2 Biosystems (NASDAQ:TTOO) following a conference call that updated multiple positive developments. Ben Haynor of AGP writes that the...
The U.S. Patent and Trademark Office (USPTO) gave INmune Bio (NASDAQ: INMB) notice of allowance for a patent, which covers the company’s INB03 program utilizing its dominant negative tumor necrosis factor–alpha (DN-TNF...
Elaine Jones Gritstone Oncology (NASDAQ:GRTS) appointed Elaine Jones as a director, replacing Peter Svennilson, founder of the Column Group and co-lead Series A investor in Gritstone. Dr. Jones was most recently VP...
William Blair launched coverage of PhaseBio Pharmaceuticals (NASDAQ:PHAS) with an “outperform” rating and risk-adjusted valuation of $16. The stock closed at $5.04 on Sept. 10. Analyst Matthew Phipps writes that his...
H.C. Wainwright upgraded AVEO Pharmaceuticals (NASDAQ:AVEO) to “buy” from “neutral” and raised its price target to $1.75 from $1, citing a positive overall survival (OS) update from the Phase 3 TIVO-3 study of tivozanib...